ArticleCureus2025
Hypertensive Heart Disease in the Nigerian Population: Prevalence, Phenotypes, and Cardiovascular Comorbidities.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Epidemiology of Pulmonary Hypertension in Sub-Saharan Africa-A Systematic Report.Pulmonary circulation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective There is a lack of studies on the phenotyping of hypertensive heart disease (HHD) that examine both left ventricular (LV) structure and function in patients with essential hypertension (HTN) in sub-Saharan Africa. In this study, we investigated the prevalence of HHD, its phenotypic characteristics, and associated cardiovascular (CV) comorbidities by analyzing both LV structure and function. This can significantly enhance the understanding of HHD in the Nigerian population. Methods This cross-sectional study involved 1,799 patients diagnosed with essential HTN, who were recruited from the Federal Medical Centre Abuja Hypertension Registry between 2016 and 2021. HHD was defined as the presence of abnormal LV geometry and/or LV diastolic dysfunction (LVDD), as assessed by echocardiography in accordance with the guidelines set by the American Society of Echocardiography and the European Association of CV Imaging. Abnormal LV geometry was characterized by either concentric remodeling, which is defined as a normal left ventricular mass index (LVMI) with a relative wall thickness (RWT) > 0.42, or left ventricular hypertrophy (LVH), which is indicated by an increased LVMI (> 95 g/m² in women and > 115 g/m² in men) with an RWT > 0.42. Patients with secondary HTN and those with HTN during pregnancy were excluded from the study. Results The mean age of the study participants was 55.3±13.0 years and the majority were female patients (55.9%). The prevalence of HHD, concentric LV remodeling, LVH, and LVDD was 90.8%, 38.2%, 47.4%, and 61.6%, respectively. After multivariate analysis, heart failure (adjusted odds ratio (OR): 9.71, confidence interval (CI) 6.20-15.23, p<0.001), stroke (OR: 1.59, CI 1.01-2.52, p=0.045), LVDD (OR: 2.01, CI 1.61-2.50, p<0.001), and female sex (OR: 1.47, CI 1.20-1.80, p<0.001) were independently and positively associated with LVH. Similarly, LVH (OR: 3.51, CI 2.53-4.87, p<0.001), diabetes mellitus (OR: 1.83, CI 1.37-2.44, p<0.001), concentric LV remodeling (OR: 2.18, CI 1.58-3.01, p<0.001), stroke (OR: 1.87, CI 1.06-3.32, p=0.032), and age ≥60 years (OR: 3.92, CI 3.09-4.96, p<0.001) were independently and positively associated with LVDD. Conclusion Our study showed a high prevalence of HHD with LVH and LVDD as common phenotypes in our hypertensive cohort. These findings suggest that the widespread use of echocardiography should be promoted to aid the early diagnosis of HHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.